According to the MHRA/EMC Summary of Product Characteristics, these include: Very common (may affect more than 1 in 10 people): Nausea Diarrhoea Common (may affect up to 1 in 10 people): Vomiting Abdominal pain Constipation Dyspepsia (indigestion) Decreased appetite These symptoms typically diminish over time as the body adjusts to the medication
Cardiovascular Outcomes and Metabolic Health Semaglutide has already proven cardiovascular benefits in trials involving high-risk type 2 diabetes patients, reducing risk of stroke and heart attack
5 Although the existing level of evidence with these new medications is limited in quality, the known mechanisms of action and current case reports indicate that patients taking GLP-1 or GLP-1/GIP receptor agonists are at a higher risk for retaining complex solid gastric contents despite following American Society of Anesthesiologists (ASA) preoperative fasting guidelines
Furthermore, the extent of such side effects depends on the desired dosage
However, that means they are also more easily excreted into the urine
This was truly an out-there idea